Tonix Pharmaceuticals Holding (TNXP) Free Cash Flow (2010 - 2026)

Tonix Pharmaceuticals Holding's Free Cash Flow history runs 17 years deep, the most recent figure standing at -$44.0 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 165.36% year-over-year to -$44.0 million in Q1 2026; TTM through Mar 2026 was -$130.6 million, a 117.92% decrease from a year earlier, with the FY2025 full-year figure at -$103.2 million, down 69.08% from the prior year.
• Free Cash Flow slipped to -$44.0 million in Q1 2026 per TNXP's latest filing, from -$41.5 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$9.9 million in Q2 2024 and bottomed at -$51.3 million in Q1 2022.
• The 5-year median for Free Cash Flow is -$27.0 million (2022), against an average of -$27.3 million.
• Across the five-year window, Free Cash Flow surged 58.96% in 2024 and slumped 183.77% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$27.0 million in 2022, then declined by 11.08% to -$30.0 million in 2023, then soared by 51.16% to -$14.6 million in 2024, then slumped by 183.77% to -$41.5 million in 2025, then retreated by 5.99% to -$44.0 million in 2026.
• Per Business Quant, the three latest TNXP Free Cash Flow figures stand at -$44.0 million (Q1 2026), -$41.5 million (Q4 2025), and -$29.8 million (Q3 2025).